Startup Lexeo Raises $85M to Pursue 3 New Gene Therapies

Startup Lexeo Raises $85M to Pursue 3 New Gene Therapies

285394

Startup Lexeo Raises $85M to Pursue 3 New Gene Therapies

Lexeo Therapeutics recently launched with an initial funding of $85 million to develop gene therapies for Friedreich’s ataxia (FA) and other disorders. The proceeds will support the clinical development of three gene therapy programs, including an anticipated Phase 1 trial this year to test LX2006 for FA-associated heart disease (cardiomyopathy). Clinical development of gene therapies for forms of Batten and Alzheimer’s disease caused by single gene mutations (monogenic conditions) will also advance with this initial funding. “We…

You must be logged in to read/download the full post.